NeoGenomics (NASDAQ:NEO) Hits New 1-Year High After Better-Than-Expected Earnings

Shares of NeoGenomics, Inc. (NASDAQ:NEO) hit a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company traded as high as $16.10 and last traded at $15.5070, with a volume of 629708 shares. The stock had previously closed at $13.40.

The medical research company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. The company had revenue of $201.66 million during the quarter, compared to analyst estimates of $196.93 million. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The firm’s revenue was up 11.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.03 earnings per share.

Key Stories Impacting NeoGenomics

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations: NeoGenomics reported adjusted earnings of $0.05 per share, ahead of the $0.03 consensus estimate, while revenue rose 11.2% year over year to $201.66 million versus expectations of $196.93 million. NeoGenomics Q2 Earnings Snapshot
• Positive Sentiment: Full-year revenue guidance was raised: Management now expects 2026 revenue of $802 million to $806 million, above the approximately $800.3 million analyst consensus. The company also highlighted a target for mid-20% growth in next-generation sequencing, or NGS, revenue. NeoGenomics 2026 Revenue Outlook
• Positive Sentiment: Needham became more bullish: Needham raised its price target from $15 to $19 and reiterated a “Buy” rating, implying substantial upside based on the referenced share price. Needham Raises NeoGenomics Price Target

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NEO shares. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a research note on Wednesday, July 15th. Benchmark lifted their price objective on shares of NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a report on Friday, July 24th. Leerink Partners raised shares of NeoGenomics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $12.00 to $25.00 in a research report on Wednesday, April 29th. Weiss Ratings upgraded shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. Finally, Needham & Company LLC raised their target price on NeoGenomics from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $15.14.

Insiders Place Their Bets

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total transaction of $59,916.03. Following the completion of the sale, the director directly owned 91,422 shares in the company, valued at approximately $1,032,154.38. The trade was a 5.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.10% of the company’s stock.

Institutional Trading of NeoGenomics

A number of institutional investors have recently made changes to their positions in the company. First Horizon Corp increased its position in shares of NeoGenomics by 52.6% during the fourth quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after purchasing an additional 865 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in NeoGenomics by 110.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock worth $35,000 after buying an additional 1,556 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of NeoGenomics during the 4th quarter valued at about $39,000. Smartleaf Asset Management LLC grew its position in NeoGenomics by 77.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock worth $42,000 after acquiring an additional 1,515 shares during the period. Finally, GAMMA Investing LLC lifted its position in NeoGenomics by 68.2% in the fourth quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock valued at $42,000 after buying an additional 1,460 shares during the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Price Performance

The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of -19.94 and a beta of 1.74. The company’s fifty day moving average is $12.39 and its two-hundred day moving average is $10.65.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.